New Haven-based Biohaven Pharmaceutical Holding Co. Ltd., a privately held biopharmaceutical company has successfully raised $80 million in private financing.

“With this financing, we have a strong financial foundation from which we can develop our late stage clinical pipeline and advance new therapies into clinical trials,” said Dr. Vlad Coric, CEO at Biohaven.

Proceeds from the financing will be used to advance the company’s late stage clinical programs for remedies to various neurologic diseases.